2019
Correlates of Future Violence in People Being Treated for Schizophrenia
Buchanan A, Sint K, Swanson J, Rosenheck R. Correlates of Future Violence in People Being Treated for Schizophrenia. American Journal Of Psychiatry 2019, 176: 694-701. PMID: 31014102, DOI: 10.1176/appi.ajp.2019.18080909.Peer-Reviewed Original ResearchConceptsClinical Antipsychotic TrialsRecent violent victimizationStudy entryMedication adherenceMultivariable analysisMental Health Clinical Antipsychotic TrialsInjurious violenceMultivariable hazard ratiosPoor medication adherenceIntervention Effectiveness (CATIE) studyLongitudinal multivariable analysesProportional hazards modelChildhood risk factorsHazard ratioMedication nonadherenceClinical variablesRisk factorsTreatment strategiesAntipsychotic TrialsBaseline symptomsClinical conditionsLarge cohortHazards modelDrug useEffectiveness studies
2018
Mental health multimorbidity and poor quality of life in patients with schizophrenia
Bhalla IP, Stefanovics EA, Rosenheck RA. Mental health multimorbidity and poor quality of life in patients with schizophrenia. Schizophrenia Research 2018, 201: 39-45. PMID: 29709490, DOI: 10.1016/j.schres.2018.04.035.Peer-Reviewed Original ResearchConceptsAdditional psychiatric comorbiditySubstance use disordersPsychiatric comorbidityPsychiatric disordersUse disordersMental health multimorbiditySubstance use comorbiditiesAdditional psychiatric disordersComorbid psychiatric disordersComorbid substance useComplex clinical presentationClinical Antipsychotic TrialsSelf-reported QoLSimilar adverse effectsMultimorbidity frameworkPoor qualityClinical presentationWorse QOLBetter QOLAntipsychotic TrialsComorbiditiesDual diagnosisQoLPatientsMultimorbidity
2015
Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.
Jakubovski E, Carlson JP, Bloch MH. Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial. The Journal Of Clinical Psychiatry 2015, 76: 1535-45. PMID: 26581028, DOI: 10.4088/jcp.14m09320.Peer-Reviewed Original ResearchConceptsIntervention Effectiveness (CATIE) trialTreatment outcomesClinical Antipsychotic TrialsBaseline characteristicsTreatment continuationCATIE trialAntipsychotic pharmacotherapyPrognostic subgroupsEffectiveness trialAntipsychotic TrialsLogistic regressionROC analysisMonths of treatmentImportant treatment outcomesDSM-IV diagnosisPatients' social isolationNegative Syndrome ScaleSocial isolationPoor outcomeZiprasidone treatmentAntipsychotic treatmentComorbid depressionSide effectsPsychosocial factorsSyndrome ScaleRandomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia
Mohamed S, Rosenheck RA, Lin H, Swartz M, McEvoy J, Stroup S. Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2015, 203: 486-492. PMID: 26075840, DOI: 10.1097/nmd.0000000000000317.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlcoholismAntipsychotic AgentsBenzodiazepinesChronic DiseaseComorbidityCross-Sectional StudiesDibenzothiazepinesDouble-Blind MethodFemaleHumansIllicit DrugsMaleMiddle AgedOlanzapinePerphenazinePiperazinesPsychiatric Status Rating ScalesQuetiapine FumarateRisperidoneSchizophreniaSchizophrenic PsychologySmokingSmoking PreventionSubstance-Related DisordersThiazolesYoung AdultConceptsSecond-generation antipsychotic drugsAntipsychotic drugsFirst-generation antipsychoticsSecond-generation antipsychoticsIntervention Effectiveness (CATIE) studySecondary outcome dataClinical Antipsychotic TrialsFirst-generation drugsSubstance use outcomesCigarette smokingSchizophrenia trialsChronic schizophreniaAntipsychotic TrialsOutcome dataNicotine useDrug useSecondary analysisPast weekAntipsychoticsEffectiveness studiesPatientsSubstance useUse outcomesTrialsDrugs
2014
Symptom structure and severity: A comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia
Stefanovics EA, Krystal JH, Rosenheck RA. Symptom structure and severity: A comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia. Comprehensive Psychiatry 2014, 55: 887-895. PMID: 24602497, DOI: 10.1016/j.comppsych.2014.01.014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntipsychotic AgentsChronic DiseaseCombat DisordersDiagnosis, DifferentialDouble-Blind MethodFemaleHumansMaleMiddle AgedPsychiatric Status Rating ScalesPsychometricsRisperidoneSchizophreniaSchizophrenic PsychologyStress Disorders, Post-TraumaticVeteransYoung AdultConceptsPost-traumatic stress disorderNegative Syndrome ScaleSyndrome ScalePTSD samplePlacebo-controlled trialPsychosis-related factorsClinical trial patientsClinical Antipsychotic TrialsT-testSchizophrenia sampleExploratory factor analysisSymptoms of schizophreniaMilitary-related post-traumatic stress disorderSymptom structureAdjunctive risperidoneTrial patientsTraumatic Stress DisorderAntipsychotic TrialsSecondary data analysisSevere symptomsIndependent factorsDepressive factorsPatientsSymptom ratingsStress disorder
2012
Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
Hermes ED, Sokoloff D, Stroup TS, Rosenheck RA. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). The Journal Of Clinical Psychiatry 2012, 73: 526-32. PMID: 22579152, PMCID: PMC3786588, DOI: 10.4088/jcp.11m07162.Peer-Reviewed Original ResearchConceptsClinical Global Impression ScalePANSS scoresClinical Antipsychotic TrialsImportant difference estimatesNegative Syndrome ScaleAntipsychotic TrialsSyndrome ScaleLong-term effectiveness trialsIntervention Effectiveness (CATIE) schizophrenia trialShort-term efficacy trialsGlobal Impression ScaleBaseline PANSS scoresLower baseline scoresClinical workIllness scoresMulticenter trialCGI scoresCGI severityImpression ScaleSchizophrenia trialsEffectiveness trialPatient ratingsEfficacy trialsImportant differencesBaseline scores
2011
Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease.
Mohamed S, Rosenheck R, Lyketsos CG, Kaczynski R, Sultzer DL, Schneider LS. Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease. The Journal Of Clinical Psychiatry 2011, 73: 121-8. PMID: 21939611, PMCID: PMC4040971, DOI: 10.4088/jcp.10m06574.Peer-Reviewed Original ResearchConceptsCaregiver Distress ScaleCaregivers of patientsSecond-generation antipsychoticsCaregiver burdenExperiences of caregiversAlzheimer's diseaseBurden InterviewDisease trialsNeuropsychiatric Inventory Caregiver Distress ScaleDistress ScaleCATIE-AD trialAtypical antipsychotic treatmentUsual care settingsAtypical antipsychotic drugsClinical Antipsychotic TrialsSymptoms of psychosisBeck Depression InventoryAD outpatientsTreat analysisAtypical antipsychoticsAntipsychotic treatmentAD patientsAntipsychotic drugsAntipsychotic TrialsCare settingsJoint Modelling of Longitudinal Outcome and Interval-Censored Competing Risk Dropout in a Schizophrenia Clinical Trial
Gueorguieva R, Rosenheck R, Lin H. Joint Modelling of Longitudinal Outcome and Interval-Censored Competing Risk Dropout in a Schizophrenia Clinical Trial. Journal Of The Royal Statistical Society Series A (Statistics In Society) 2011, 175: 417-433. PMID: 22468033, PMCID: PMC3315284, DOI: 10.1111/j.1467-985x.2011.00719.x.Peer-Reviewed Original ResearchLongitudinal outcomesClinical Antipsychotic TrialsQuality of lifeSchizophrenia clinical trialsStudy medicationAntipsychotic medicationClinical trialsAntipsychotic TrialsStudy participantsPhase IIntervention effectivenessMedicationsSignificant differencesSelection biasTrialsOutcomesJoint modelling approachCauses of dropoutLarge percentageParticipantsTolerabilityPatientsOutcome valuesEffect of dropoutStudy schedule
2010
Housing arrangements among a national sample of adults with chronic schizophrenia living in the United States: a descriptive study
Tsai J, Stroup T, Rosenheck R. Housing arrangements among a national sample of adults with chronic schizophrenia living in the United States: a descriptive study. Journal Of Community Psychology 2010, 39: 76-88. DOI: 10.1002/jcop.20418.Peer-Reviewed Original ResearchCriminal Justice System Involvement Among People with Schizophrenia
Greenberg G, Rosenheck RA, Erickson SK, Desai RA, Stefanovics EA, Swartz M, Keefe RS, McEvoy J, Scott Stroup T, Other CATIE Investigators. Criminal Justice System Involvement Among People with Schizophrenia. Community Mental Health Journal 2010, 47: 727-736. PMID: 21113799, DOI: 10.1007/s10597-010-9362-9.Peer-Reviewed Original ResearchConceptsMultivariate logistic regression analysisLogistic regression analysisCJS involvementDrug abuseSystem involvementCriminal justice system involvementCo-morbid drug abuseBaseline clinical statusSymptoms of akathisiaPotential risk factorsSevere mental illnessClinical Antipsychotic TrialsRegression analysisJustice system involvementBivariate chi-squarePatient characteristicsClinical statusRisk factorsAntipsychotic TrialsPsychiatric statusService useAdolescent conduct disorderMental illnessSociodemographic characteristicsBivariate analysisCaregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates
Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS. Caregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates. American Journal Of Geriatric Psychiatry 2010, 18: 917-927. PMID: 20808108, PMCID: PMC3972419, DOI: 10.1097/jgp.0b013e3181d5745d.Peer-Reviewed Original ResearchConceptsAlzheimer's diseasePatients' qualityCaregiver burdenCognitive statusCaregiver Distress ScaleUsual care settingsIntensity of careLower functional capabilitySix-month changesClinical Antipsychotic TrialsProbable Alzheimer's diseasePatients' cognitive statusDiagnosis of dementiaQuality of lifeBeck Depression InventoryCATIE-ADRelationship of burdenBurden InterviewAmbulatory outpatientsPatients CorrelatePharmacologic interventionsAntipsychotic TrialsTreatment outcomesDecreased burdenCare settingsImpact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. The Journal Of Clinical Psychiatry 2010, 72: 75-80. PMID: 20868641, PMCID: PMC5052810, DOI: 10.4088/jcp.09m05258gre.Peer-Reviewed Original ResearchConceptsMajor depressive episodeSecond-generation antipsychoticsDSM-IV-defined schizophreniaCurrent major depressive episodeClinical practice recommendationsTrial of treatmentClinical practice guidelinesTreatment of depressionCalgary Depression ScaleClinical Antipsychotic TrialsSecond-generation drugsSymptoms of depressionPhase 1 analysisTardive dyskinesiaDepressive episodeChronic schizophreniaAntipsychotic TrialsPractice guidelinesDepression ScaleDepressive symptomsTreatment groupsBaseline scoresPatientsAntipsychoticsPractice recommendationsVocational outcomes
Resnick S, Rosenheck R. Vocational outcomes. 2010, 120-132. DOI: 10.1017/cbo9780511712265.008.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesVocational outcomesPsychiatric researchersTrialsDrugsPharmaceutical companiesSpecific outcomesOutcomesStatistical analysisCliniciansExtrapyramidal side effects
Caroff S, Miller D, Rosenheck R. Extrapyramidal side effects. 2010, 156-172. DOI: 10.1017/cbo9780511712265.010.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersExtrapyramidal side effectsDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsSide effectsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsDrugsPharmaceutical companiesSpecific outcomesStatistical analysisCliniciansConclusion and implications for practice and policy
Rosenheck R, Stroup T, Lieberman J. Conclusion and implications for practice and policy. 2010, 288-306. DOI: 10.1017/cbo9780511712265.018.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsDrugsPharmaceutical companiesSpecific outcomesStatistical analysisCliniciansFamily outcomes
Perlick D, Kaczynski R, Rosenheck R. Family outcomes. 2010, 133-155. DOI: 10.1017/cbo9780511712265.009.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsFamily outcomesDrugsPharmaceutical companiesSpecific outcomesOutcomesStatistical analysisClinicians
2009
Impact of antipsychotic medication on family burden in schizophrenia: Longitudinal results of CATIE trial
Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA. Impact of antipsychotic medication on family burden in schizophrenia: Longitudinal results of CATIE trial. Schizophrenia Research 2009, 116: 118-125. PMID: 19864114, DOI: 10.1016/j.schres.2009.09.026.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsAttitude to HealthCaregiversCost-Benefit AnalysisDouble-Blind MethodFamilyFemaleHumansLongitudinal StudiesMaleMiddle AgedPsychiatric Status Rating ScalesQuality of LifeRegression AnalysisSchizophreniaSchizophrenic PsychologySeverity of Illness IndexStatistics, NonparametricTreatment OutcomeConceptsSecond-generation antipsychoticsSecond-generation drugsFamily burdenTreatment assignmentInitial treatment assignmentSecond-generation medicationsClinical Antipsychotic TrialsEvidence of superiorityMedication changesCATIE trialInitial medicationPatient's symptomsAntipsychotic medicationAntipsychotic TrialsDaily livingFamily caregiversService useSide effectsMedicationsSecondary analysisPatientsIntervention effectivenessBurden factorsTrialsAntipsychotics
2008
Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia
Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. Schizophrenia Bulletin 2008, 35: 336-346. PMID: 18586692, PMCID: PMC2659303, DOI: 10.1093/schbul/sbn067.Peer-Reviewed Original ResearchConceptsPositive medication attitudesMedication attitudesSymptoms of schizophreniaSchizophrenia symptomsGreater medication complianceDrug Attitude InventoryRelationship of insightClinical Antipsychotic TrialsTreatment Attitudes QuestionnaireGreater patient understandingLevel of depressionMixed model regression analysisLower symptom levelsRecovery-oriented servicesClinical outcomesMedication adherenceMedication complianceChronic schizophreniaAntipsychotic TrialsPatient understandingModel regression analysisMedicationsCommunity functioningPsychosocial rehabilitationSymptoms
2006
Effectiveness of Switching Antipsychotic Medications
Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of Switching Antipsychotic Medications. American Journal Of Psychiatry 2006, 163: 2090-2095. PMID: 17151159, DOI: 10.1176/ajp.2006.163.12.2090.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsBenzodiazepinesCross-Over StudiesDibenzothiazepinesDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleHumansMiddle AgedOlanzapinePatient DropoutsPsychotherapyQuetiapine FumarateResearch DesignRisperidoneSchizophreniaSchizophrenic PsychologySelection BiasSurvival AnalysisTreatment OutcomeConceptsMedication changesDifferent antipsychoticsCause treatment discontinuationCurrent medication regimensClinical Antipsychotic TrialsPhase 1 analysisPhase 1 findingsBaseline medicationsSwitching medicationsTreatment discontinuationMedication regimensPrimary outcomeMedication effectivenessAntipsychotic medicationAntipsychotic TrialsMedicationsAntipsychoticsClinical situationsOlanzapinePatientsRisperidoneIntervention effectivenessDearth of informationDiscontinuationRandom assignmentEffectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Stroup T, Lieberman J, McEvoy J, Swartz M, Davis S, Rosenheck R, Perkins D, Keefe R, Davis C, Severe J, Hsiao J. Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. FOCUS The Journal Of Lifelong Learning In Psychiatry 2006, 4: 539-552. DOI: 10.1176/foc.4.4.539.Peer-Reviewed Original ResearchAtypical antipsychoticsChronic schizophreniaDouble-blind treatmentDouble-blind studyGroup of patientsDifferent atypical antipsychoticsEffectiveness of olanzapineTreatment of schizophreniaClinical Antipsychotic TrialsTreatment discontinuationPrevious antipsychoticDifferent antipsychoticsAntipsychotic TrialsAntipsychoticsQuetiapineDiscontinuationPatientsOlanzapineRisperidoneZiprasidonePrevious treatmentSchizophreniaTreatmentSignificant differencesPrimary aim
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply